论文部分内容阅读
目的 探讨两种剂量结合雌激素 (CEE)对绝经早期妇女骨丢失的影响及副作用。方法将 2 36例绝经妇女分为 3组 ,A组每日口服CEE 0 62 5mg+醋甲羟孕酮 (MPA) 2mg +钙剂 (Ca D) 1片(含元素钙 60 0mg) ;B组每日口服CEE 0 3mg +MPA 2mg +Ca D 1片 ;C组每日仅服Ca D 1片 ,连续用药 2年。于治疗前、治疗 1 2及 2 4个月测量第 2～ 4腰椎 (L2～ 4 )的骨密度 (BMD) ,记录每月阴道出血情况。结果 A组治疗前、治疗 1 2及 2 4个月 ,L2～ 4 BMD分别为 (1 0 62± 1 4 1 )、(1 0 86± 1 4 5)及 (1 1 0 1±1 34)mg/cm2 ,治疗前后比较 ,差异均有极显著性 (P <0 0 0 1 ) ;B组分别为 (1 0 81± 1 35)、(1 1 1 1± 1 68)及(1 0 90± 1 50 )mg/cm2 ,治疗 1 2个月时与治疗前比较 ,差异有显著性 (P <0 0 5) ,治疗 2 4个月时与治疗前比较 ,差异无显著性 (P >0 0 5) ;C组分别为 (1 0 70± 1 1 9)、(1 0 65± 1 34)及 (1 0 53± 1 30 )mg/cm2 ,治疗前后比较 ,差异均无显著性 (P >0 0 5)。治疗前后BMD的变化 ,A与C组、B与C组之间差异均有显著性 (P <0 0 0 1 ,<0 0 5) ;A与B组治疗 1 2个月时的BMD比较 ,差异无显著性 (P >0 0 5) ,2 4个月时比较 ,差异有极显著性 (P <0 0 1 )。各组子宫内膜均无不典型增生。A、B组出血率 ,治
Objective To investigate the effects of two doses of estrogen (CEE) on bone loss in early postmenopausal women and its side effects. Methods Two hundred and thirty-three menopausal women were divided into three groups. Group A received daily CEE 0 62 5 mg, MPA 2 mg and calcium (Ca D) 1 (containing 60 mg of elemental calcium); Group B The daily oral administration of CEE 0 3mg + MPA 2mg + CaD 1 tablets; C group daily serving only CaD 1 tablets, continuous medication for 2 years. BMD of L2 ~ 4 lumbar spine (L2 ~ 4) was measured before treatment, 12 and 24 months after treatment, and monthly vaginal bleeding was recorded. Results Before treatment, the L2 ~ 4 BMD of group A was (122 ± 1 41), (1 861 45) and (1 1 0 1 1 34) respectively, mg / cm2, the difference was significant (P <0.01) before and after treatment; the group B was (1 0 81 ± 1 35), (1 1 1 1 ± 1 68) and (1 0 90 ± 1 50) mg / cm2. There was a significant difference between the two groups (P <0.05) at 12 months of treatment and before treatment, but no significant difference was found between the two groups (P <0.05). There was no significant difference between before and after treatment in the group C (10 70 ± 1 1 9), (1 0 65 ± 1 34) and (1 533 ± 1 30) mg / > 0 0 5). The changes of BMD before and after treatment showed that there was significant difference between A group and C group and between B group and C group (P <0 01 1, <0 05). Compared with BMD of group A and B at 12 months, There was no significant difference between the two groups (P> 0.05). The difference was significant at 24 months (P <0.01). Each group had no typical endometrial hyperplasia. A, B group bleeding rate, treatment